A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
Clinical trial NCT03978611 · TERMINATED
Trial details
- NCT number
- NCT03978611
- Sponsor
- Bristol-Myers Squibb
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-09
- Primary completion
- 2023-07-26
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.